Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

This French company has received regulatory approval to market its total artificial heart system in EU

Editorial team by Editorial team
January 5, 2021
in Health & Medtech, News, Startups
0
This French company has received regulatory approval to market its total artificial heart system in EU

Image credits: CARMAT

24
SHARES
LinkedInTwitterWhatsAppFacebook

Heart diseases such as chronic and acute heart failure are considered to be among the world’s leading causes of death. By designing and developing the world’s first-ever most advanced total artificial heart, Paris-based CARMAT aims to fulfil the unmet medical need to people suffering from end-stage biventricular heart failure.

In a recent development, CARMAT announced that it had received the CE marking for its artificial heart system. The CE marking was granted on December 22, 2020, to its total artificial heart system as a bridge to transplant in patients suffering from end-stage biventricular heart failure (Intermacs Classes 1-4) who are not amenable to maximal medical therapy or the LVAD1 and who are likely to undergo a heart transplant in the 180 days following implantation.

 - Partner content -
Cost of software - The Software house
The cost of building software
Marek Gajda, CTO of The Software House, shares his insights on building high-quality...Show More
Marek Gajda, CTO of The Software House, shares his insights on building high-quality software. Show Less
Read more

Eyes to ramp up production

The CE marking lets CARMAT market its total artificial heart system in all countries, including those from the European Union that recognise the certification. The company will accelerate the production of this artificial heart system and launch the same commercially in the second quarter of this year. Eventually, it will offer a solution to numerous patients waiting for a heart transplant.

Stéphane Piat, Chief Executive Officer of CARMAT, says, “The CE Marking is great news for patients and a major milestone for CARMAT. As early as January, we will accelerate the ramp-up of our manufacturing activities and intensify discussions with our core target customers in order to achieve a smooth commercial launch during the second quarter of 2021, and thus offer a solution to many patients waiting for a heart transplant.”

Shares soars

After the company obtained its CE marking, its shares posted their biggest gain in more than seven years, according to Bloomberg. In late December 2020, the stock climbed 34 per cent to €32.05 in Paris after rising as much as 50 per cent – its steepest intraday gain since May 2013. In 2020, the company’s shares advanced 66 per cent, providing the company with a market value of about €407M ($496M).

About CARMAT

With the artificial heart system, CARMAT intends to overcome the shortfall in heart transplants faced by tens of thousands of people suffering from irreversible end-stage heart failure. The company is run by the medical expertise of Alain Carpentier – known for inventing Carpentier-Edwards heart valves – and the technological expertise of the Airbus Group.

Last year, in October, the company was granted €13M in funding by the French Ministry of Health and Solidarity to conduct the EFICAS clinical study, already approved by the HAS (the French health authority) in April 2020.

Through the budget agreement with the French Ministry of Health and Solidarity, two-thirds of the total cost of the EFICAS study will be funded by the French state, which represents non-dilutive financing of €13M for CARMAT.

According to the company, it has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33m, with the backing of the European Commission.

CARMAT is backed by Matra Défense SAS (a subsidiary of the Airbus Group), Professor Alain Carpentier, the Centre Chirurgical Marie Lannelongue, Truffle Capital, a leading European venture capital firm, ALIAD (Air Liquide’s venture capital investor), CorNovum (an investment holding company held 50-50 by Bpifrance and the French State), the family offices of Pierre Bastid (Lohas), Dr Antonino Ligresti (Santé Holdings S.R.L.), the Gaspard family (Corely Belgium SPRL and Bratya SPRL) and M. Pierre-Edouard Stérin (BAD 21 SPRL), Groupe Therabel as well as the thousands of institutional and individual shareholders.

close

Want to stay on top of the latest rounds, coolest tech and hottest startups?

Subscribe to our free, daily news blast and stay up-to-date!

Check your inbox or spam folder to confirm your subscription.

 - Partner content -
Hiring during COVID Intrinsic Search
Hiring SaaS sales executives
Check out the do's and don'ts while hiring SaaS sales executives
Check out the do's and don'ts while hiring SaaS sales executives Show Less
Read more
Tags: French Startupsmedtech
Share2Tweet6SendShare10

Partner content | Work with us

Future of coding: CTOs discuss low-code versus custom code software development for their business

Why now is the perfect time to start hiring for 2021

SaaS sales in 2021: 9 predictions from an industry expert

Diversity in hiring for SaaS: the often overlooked topic of ageism

Boost your scale-up’s growth by outsourcing to these top Eastern European software development companies

Subscribe to our daily newsletter

Check your inbox or spam folder to confirm your subscription.

Breaking news from Amsterdam | Partner

Here’s why Just Eat Takeaway wants to remain listed in Amsterdam

CES 2021: Meet the 12 Amsterdam-based startups in the Dutch delegation

11 AI leaders from Amsterdam to watch in 2021

Amsterdam-based Media Distillery uses AI to understand what’s inside video; secures €3M

Advertisement

Trending

Adobe flash
News

Adobe pulls the plug on Flash, but here’s how you can still play some iconic Adobe Flash games

January 4, 2021
Amsterdam
Amsterdam

CES 2021: Meet the 12 Amsterdam-based startups in the Dutch delegation

January 13, 2021
3D Hubs
Amsterdam

Amsterdam-based 3D Hubs acquired by Protolabs for €272.1M; here’s what you need to know

January 19, 2021
  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy policy
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2020 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdam
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact

Silicon Canals 2014-2020 | Website: Bright Idiots

X

This website uses cookies to ensure the best possible experience. We may share this information with our advertising and analytics partners. By clicking 'Accept', you agree to our use of cookies and similar technologies. More info